Literature DB >> 11559825

Cellular membrane-binding ability of the C-terminal cytoplasmic domain of human immunodeficiency virus type 1 envelope transmembrane protein gp41.

S S Chen1, S F Lee, C T Wang.   

Abstract

The amphipathic alpha-helices located in the cytoplasmic tail of the envelope (Env) transmembrane glycoprotein gp41 of human immunodeficiency virus type 1 have been implicated in membrane association and cytopathicity. Deletion of the last 12 amino acids in the C terminus of this domain severely impairs infectivity. However, the nature of the involvement of the cytoplasmic tail in Env-membrane interactions in cells and the molecular basis for the defect in infectivity of this mutant virus are still poorly understood. In this study we examined the interaction of the cytoplasmic tail with membranes in living mammalian cells by expressing a recombinant cytoplasmic tail fragment and an Escherichia coli beta-galactosidase/cytoplasmic tail fusion protein, both of them lacking gp120, the gp41 ectodomain, and the transmembrane region. We found through cell fractionation, in vivo membrane flotation, and confocal immunofluorescence studies that the cytoplasmic tail contained determinants to be routed to a perinuclear membrane region in cells. Further mapping showed that each of the three lentivirus lytic peptide (LLP-1, LLP-2, and LLP-3) sequences conferred this cellular membrane-targeting ability. Deletion of the last 12 amino acids from the C terminus abolished the ability of the LLP-1 motif to bind to membranes. High salt extraction, in vitro transcription and translation, and posttranslational membrane binding analyses indicated that the beta-galactosidase/LLP fusion proteins were inserted into membranes via the LLP sequences. Subcellular fractionation and confocal microscopy studies revealed that each of the LLP motifs, acting in a position-independent manner, targeted non-endoplasmic reticulum (ER)-associated beta-galactosidase and enhanced green fluorescence protein to the ER. Our study provides a basis for the involvement of the gp41 cytoplasmic tail during Env maturation and also supports the notion that the membrane apposition of the C-terminal cytoplasmic tail plays a crucial role in virus-host interaction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11559825      PMCID: PMC114564          DOI: 10.1128/JVI.75.20.9925-9938.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  71 in total

1.  Multimerization potential of the cytoplasmic domain of the human immunodeficiency virus type 1 transmembrane glycoprotein gp41.

Authors:  S F Lee; C T Wang; J Y Liang; S L Hong; C C Huang; S S Chen
Journal:  J Biol Chem       Date:  2000-05-26       Impact factor: 5.157

2.  The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions.

Authors:  T Murakami; E O Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

3.  Human immunodeficiency virus envelope protein determines the site of virus release in polarized epithelial cells.

Authors:  R J Owens; J W Dubay; E Hunter; R W Compans
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

4.  A structural correlation between lentivirus transmembrane proteins and natural cytolytic peptides.

Authors:  M A Miller; R F Garry; J M Jaynes; R C Montelaro
Journal:  AIDS Res Hum Retroviruses       Date:  1991-06       Impact factor: 2.205

5.  A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity.

Authors:  E O Freed; E L Delwart; G L Buchschacher; A T Panganiban
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

6.  Cell-dependent requirement of human immunodeficiency virus type 1 gp41 cytoplasmic tail for Env incorporation into virions.

Authors:  H Akari; T Fukumori; A Adachi
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

7.  Effect of nonpolar substitutions of the conserved Phe11 in the fusion peptide of HIV-1 gp41 on its function, structure, and organization in membranes.

Authors:  M Pritsker; J Rucker; T L Hoffman; R W Doms; Y Shai
Journal:  Biochemistry       Date:  1999-08-31       Impact factor: 3.162

8.  trans-dominant interference with human immunodeficiency virus type 1 replication and transmission in CD4(+) cells by an envelope double mutant.

Authors:  S S Chen; S F Lee; C K Chuang; V S Raj
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

9.  Membrane association of functional vesicular stomatitis virus matrix protein in vivo.

Authors:  L D Chong; J K Rose
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

10.  Identification and immunolocalization of calreticulin in pancreatic cells: no evidence for "calciosomes".

Authors:  M Michalak; S Baksh; M Opas
Journal:  Exp Cell Res       Date:  1991-11       Impact factor: 3.905

View more
  26 in total

1.  Differential functional phenotypes of two primary HIV-1 strains resulting from homologous point mutations in the LLP domains of the envelope gp41 intracytoplasmic domain.

Authors:  Jason T Newman; Timothy J Sturgeon; Phalguni Gupta; Ronald C Montelaro
Journal:  Virology       Date:  2007-06-19       Impact factor: 3.616

2.  Membrane structure correlates to function of LLP2 on the cytoplasmic tail of HIV-1 gp41 protein.

Authors:  Alexander L Boscia; Kiyotaka Akabori; Zachary Benamram; Jonathan A Michel; Michael S Jablin; Jonathan D Steckbeck; Ronald C Montelaro; John F Nagle; Stephanie Tristram-Nagle
Journal:  Biophys J       Date:  2013-08-06       Impact factor: 4.033

Review 3.  Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme.

Authors:  Judith M White; Sue E Delos; Matthew Brecher; Kathryn Schornberg
Journal:  Crit Rev Biochem Mol Biol       Date:  2008 May-Jun       Impact factor: 8.250

4.  Effects of stabilization of the gp41 cytoplasmic domain on fusion activity and infectivity of SIVmac239.

Authors:  Andrei N Vzorov; Richard W Compans
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-04       Impact factor: 2.205

5.  Genomic analysis of an effective lentiviral vaccine-attenuated equine infectious anemia virus vaccine EIAV FDDV13.

Authors:  Xu Qi; Xuefeng Wang; Shuai Wang; Yuezhi Lin; Chenggang Jiang; Jian Ma; Liping Zhao; Xiaoling Lv; Rongxian Shen; Fenglong Wang; Xiangang Kong; Zhiqiang Su; Jianhua Zhou
Journal:  Virus Genes       Date:  2010-06-05       Impact factor: 2.332

6.  Characterization of hepatitis C virus core protein multimerization and membrane envelopment: revelation of a cascade of core-membrane interactions.

Authors:  Li-Shuang Ai; Yu-Wen Lee; Steve S-L Chen
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

7.  Effect of extension of the cytoplasmic domain of human immunodeficiency type 1 virus transmembrane protein gp41 on virus replication.

Authors:  Woan-Eng Chan; Ya-Lin Wang; Hui-Hua Lin; Steve S-L Chen
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 envelope glycoproteins that lack cytoplasmic domain cysteines: impact on association with membrane lipid rafts and incorporation onto budding virus particles.

Authors:  Jayanta Bhattacharya; Paul J Peters; Paul R Clapham
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

9.  Matrix and envelope coevolution revealed in a patient monitored since primary infection with human immunodeficiency virus type 1.

Authors:  Elodie Beaumont; Daniela Vendrame; Bernard Verrier; Emmanuelle Roch; François Biron; Françis Barin; Fabrizio Mammano; Denys Brand
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

10.  An alteration of human immunodeficiency virus gp41 leads to reduced CCR5 dependence and CD4 independence.

Authors:  Brian M Taylor; J Scott Foulke; Robin Flinko; Alonso Heredia; Anthony DeVico; Marvin Reitz
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.